Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma
Aditya Juloori, Rohan Katipally, Jeffrey M. Lemons, Anurag K. Singh, Renuka Iyer, Jared R. Robbins, Ben George, William A. Hall, Sean P. Pitroda, Fauzia Arif, John J. Fung, Anjana Pillai, Chih‐Yi Liao, Manish Sharma, Stanley L. Liauw
Topics & Concepts
MedicineNivolumabIpilimumabClinical endpointResponse Evaluation Criteria in Solid TumorsInternal medicineOncologyHepatocellular carcinomaAdverse effectPhases of clinical researchRandomized controlled trialSurgeryClinical trialImmunotherapyCancerHepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersCholangiocarcinoma and Gallbladder Cancer Studies